Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.50 |
| ▸ | CTSS | P25774 | 2/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 10/20 | 0.46 |
| ▸ | AR | P10275 | 2/20 | 0.45 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7241206 | 0.88 | CHIA (0.59) | TSHRHSD17B10CAPN1CTSSCHIA | |
| SCHEMBL7239763 | 0.87 | HSD17B10 (0.56) | TSHRHSD17B10CAPN1CTSSCHIA | |
| SCHEMBL7243628 | 0.87 | CAPN1 (0.64) | TSHRHSD17B10CAPN1CTSSABCB1 | |
| SCHEMBL7233171 | 0.86 | CAPN1 (0.57) | TSHRHSD17B10CAPN1CTSSCHIA | |
| SCHEMBL7242743 | 0.85 | TSHR (0.54) | TSHRHSD17B10CAPN1CTSSABCB1 | |
| SCHEMBL7241988 | 0.84 | CAPN1 (0.59) | TSHRHSD17B10CAPN1CTSSCHIA | |
| SCHEMBL7232927 | 0.84 | CAPN1 (0.54) | TSHRHSD17B10CAPN1CTSSCHIA | |
| SCHEMBL7243112 | 0.84 | TSHR (0.55) | TSHRHSD17B10CAPN1CTSSCHIA | |
| SCHEMBL7235665 | 0.83 | CAPN1 (0.55) | TSHRHSD17B10CAPN1CTSSCHIA | |
| SCHEMBL7232626 | 0.82 | TSHR (0.53) | TSHRHSD17B10CAPN1CTSSABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6562827-B1 | For the treatment of diseases in which increased calpain activity occurs such as neurodegenerative diseases or neuronal damage are caused by ischemia, trauma or mass hemorrhages | ABBOTT LABORATORIES | 2003-05-13 | — | — | US | disclosed |